Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
AstraZeneca ranked third in the Japan pharma sales ranking in 2021, up by one notch from the prior year, becoming the fastest growing company in the top 10 list with growth of over 12%, its local helmsman Stefan Woxström said…
To read the full story
Related Article
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
- AstraZeneca Looks to Become Top Drug Maker in Japan by 2025
April 7, 2021
BUSINESS
- Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…